title: [Risk minimization evolution of agranulocytosis caused by the administration of pharmaceutical products containing Clozapine in Argentina].
abstract: Clozapine is an antipsychotic medication used in the treatment of schizophrenia. Compared to other drugs, Clozapine has shown remarkable advantages. However, its use entails a serious risk of causing hematologic alterations (including granulocytopenia/agranulocytosis). Such alterations may result in death if they are not detected early. Clozapine was recalled from the worldwide market and it was reintroduced some years later, but a mandatory hematologic monitoring program was implemented. The program was established in Argentina by ANMAT's regulation 935/00. It helped to monitor of the use of the drug. Currently, the incidence of agranulocytosis in our country is lower than the international incidence rates.
authors: Médico Pediatra integrante del Departamento de Farmacovigilancia de la ANMAT. snfvg@anmat.gov.ar
authors: Maximiliano
authors: M
authors: Bergman
authors: Inés
authors: I
authors: Bignone
authors: Agustina
authors: A
authors: Bisio
authors: Viviana
authors: V
authors: Bologna
authors: Analía
authors: A
authors: Sabatini
mesh_terms: D000380:Agranulocytosis / Q000139:chemically induced* / Q000517:prevention & control; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001118:Argentina; D003024:Clozapine / Q000009:adverse effects*; D006801:Humans; D012307:Risk Factors; D012308:Risk Management
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine